Cagrilintide

Also known as: AM833, Cagrilintide

Metabolic

Phase III

Cagrilintide is a once-weekly amylin analog currently in pivotal Phase 3 trials as part of the CagriSema combination (with semaglutide). Acting on a complementary pathway to GLP-1, amylin analogs suppress glucagon, slow gastric emptying, and promote satiety through different brain circuits — providing additive weight loss when combined with GLP-1 agonists.

Regulatory & Approval Status

Not FDA Approved

Cagrilintide is currently in Phase 3 clinical trials as a monotherapy and in combination with semaglutide (CagriSema); it is not FDA-approved.

Information compiled from FDA compounding guidance and public regulatory sources. For research and educational purposes only; not medical advice.

Unlock the complete research profile

Create your free CertifiedTide account to access full compound details, mechanisms, safety data, and research tools.